ClinicalTrials.gg
RecruitingNCT05837624ERASEUpdated Nov 3, 2026

Estetrol/Drospirenone to Reduce the Average Size of Endometriomas

A Phase 4 interventional study of Estetrol/Drospirenone in Ovarian Endometrioma and Endometrioma, sponsored by Andrew Zakhari. Recruiting at 1 site in Canada. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Andrew Zakhari · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.
Updated Nov 3, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
21
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies in Endometriosis with a site in Canada — 12 open to participants now, 13 under way, none of them phase 3. Endometriosis · Canada.

Planned enrollment
17th of 23
21 · median 64
Started
2024
with 4 others
Phase 4
Only one
of the 34
Primary completion
2027-07
later than 7 of 12 live
Registered
24th of 34
by date
Lead sponsor
1 of 34
Andrew Zakhari

Among the 34 studies in Endometriosis with a site in Canada, this one is the 17th largest by planned enrollment of the 23 interventional ones that give a count, is one of 5 that started in 2024, is the only one in phase 4, reaches primary completion later than 7 of the 12 other live ones, and was the 24th registered.

Endometriosis

924 studies on the registry are indexed under Endometriosis; 268 are open to participants now.

Browse Endometriosis studies →

Open to participants now

12 of the 34 studies in Endometriosis with a site in Canada are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 180 Endometriosis studies recruiting now, 53 (29%) set no upper age limit and 125 (69%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Endometriosis with a site in Canada, or all of them as a file.
02

Study summary

Endometriosis, a chronic gynecological disorder associated with pain and infertility, is a common condition affecting approximately one in ten women. Up to 50% of patients with endometriosis have ovarian endometriomas (or "chocolate cysts"). These cysts directly impact fertility and ovarian reserve (ie. ability to have children) and can cause additional symptoms in women such as added pain, discomfort, and surgical emergencies (cyst rupture, or more rarely twisting). While endometriomas tend to require surgical excision as a solution, medical management with a variety of medications has been shown to be effective in reducing their size.

Medical management (ie. medications and treatments that don't involve surgery) to reduce cyst size can help relieve symptoms either as a long term solution, before fertility treatments, or temporarily until surgery can be offered. Because the COVID-19 pandemic caused significantly reduced access to surgery and resources, medical management has become important for relief of the overburdened healthcare network.

The purpose of this study is to see how effective Estetrol/drospirenone, a combined oral contraceptive (COC), is in the reduction of ovarian endometriomas after a 3- and 6-month period of treatment.

This single arm interventional study will recruit women 18 years or older with an ovarian endometrioma of at least 3cm, who are seeking a hormonal treatment for their endometrioma(s). Consenting participants of the study will take Estetrol/drospirenone once daily, orally, for a 6 month duration. An ultrasound assessment of ovarian endometrioma(s) will be performed before starting the drug (0 months), and will be repeated at 3-months and 6-months time. At each of these hospital visits (0, 3 \& 6 months), participants will have their weight and blood pressure measured, and they will complete questionnaires regarding their endometriosis symptoms, incidence of amenorrhea, compliance and incidence of any adverse effects.

Read the detailed description

Ovarian endometriomas (or "chocolate cysts") are present in up to 50% of patients with endometriosis - a chronic gynecological disorder associated with pain and infertility. These cysts directly impact fertility and ovarian reserve and can cause additional symptoms in women such as added pain, discomfort, and surgical emergencies (cyst rupture, or more rarely torsion).

While endometriomas tend to require surgical excision for definitive resolution, medical management with a variety of agents has been shown to be effective in reducing their size; these agents include combined oral contraceptives (COC), aromatase inhibitors, progestins, androgens, cabergoline, and gonadotropin-releasing hormone agonists (GnRH-a). Medical management to reduce their size can help alleviate symptoms indefinitely without damaging ovarian reserve prior to fertility treatments, or to temporize until surgical management can be offered. Medical management has become particularly important in light of the COVID-19 pandemic, with significantly reduced access to surgery, and resource allocation to alleviate an overburdened healthcare network.

Estetrol/drospirenone (Nextstellis™) is a prescription-only COC available in Canada containing two hormones: a progestin (drospirenone - well known as both a standalone contraceptive and in other combined formulations), and an estrogen (estetrol - newly introduced with this product). While ethinyl estradiol (EE) is the most common estrogen currently used in COC, estetrol (E4) has proven safety and tolerability, and emerging evidence points towards a lower risk of thrombosis than traditional EE used in other COC. Studies have documented efficacy and safety for the combination estetrol/drospirenone, with a favourable bleeding profile, and very low rates of adverse reactions. While there exists already encouraging data on drospirenone and drospirenone containing products on alleviating symptoms of endometriosis and reducing the size of endometriomas, there are no studies to date evaluating this novel combination of estetrol/drospirenone in managing ovarian endometriomas.

The primary objective of this study is to determine the effectiveness of Estetrol/drospirenone, a combined oral contraceptive (COC), in the reduction of ovarian endometriomas after a 3- and 6-month period of treatment.

This is a single-center, open label, single arm interventional study that will be performed at the McGill University Health Centre (MUHC) Royal Victoria Hospital (RVH). Women 18 years of age or older with at least one ovarian endometrioma, of at least 3cm, who are seeking a hormonal treatment for their endometrioma(s), will be recruited. The study will aim to recruit 21 women.

Consenting participants will be given a 6-month course of oral estetrol/drospirenone (15 mg estetrol monohydrate / 3 mg drospirenone) once daily for the study duration. An ultrasound assessment of ovarian endometrioma(s) will be performed prior to drug initiation (baseline), and will be repeated at 3-months and 6-months time. All ultrasounds will be performed by the same ultrasonographer using a standardized technique and 3-D volumetric assessment. At each of these hospital visits, participants will have their weight and blood pressure measured and they will complete questionnaires regarding their endometriosis symptoms with a research coordinator. Safety, tolerability, and the incidence of adverse effects will also be monitored at the same time intervals.

03

Conditions studied

  • Ovarian Endometrioma
  • Endometrioma

Browse trials for

Keywords

  • Estetrol/drospirenone
  • Nextstellis
  • Endometriosis
  • volume reduction
  • ultrasound
  • Estetrol-drospirenone
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Equal to or greater than 18 years old
  • Has at least one ovarian endometrioma, of at least 3 cm
  • Seeking a hormonal treatment for their endometrioma(s)

Exclusion criteria

Exclusion criteria:

  • Any allergy or to the study drug
  • Inability to provide
  • Any hormone use, from the following list, within last 3 months (excluding hormones used for ovarian stimulation for fertility treatments): Estrogen (agonist or antagonist), Progestogen (agonist or antagonist), Androgen (agonist or antagonist), GnRH (agonist or antagonist), Cabergoline
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (estimated)

Study arms

  • Experimental
    Women with an ovarian endometrioma who will take drospirenone / estetrol

    Women 18 years of age or older with endometriosis who have at least one ovarian endometrioma, of at least 3 cm in diameter, who will take oral Drospirenone / Estetrol treatment for 6 months

    Drug: Estetrol/Drospirenone

Interventions

06

What researchers measure

Primary outcomes

  1. Change in ovarian endometrioma volume at 6-months (from baseline)

    Endometrioma volume will be assessed by the same ultrasonographer (Dr. DB Nguyen) at each hospital visit, using a standardized technique, with 3-dimensional volumetric assessment.

    Time frame: pre-study, 6-months of treatment

Secondary outcomes

  1. Change in endometrioma volume at 3-months (from baseline)

    Endometrioma volume will be assessed by the same ultrasonographer (Dr. DB Nguyen) at each hospital visit, using a standardized technique, with 3-dimensional volumetric assessment.

    Time frame: pre-study, 3-months of treatment

  2. change in endometrioma maximal diameter at 6-months (from baseline)

    Endometrioma maximal diameter will be assessed by the same ultrasonographer (Dr. DB Nguyen) at each hospital visit, using a standardized technique, with 3-dimensional volumetric assessment.

    Time frame: pre-study, 6-months of treatment

  3. change in endometrioma maximal diameter at 3-months (from baseline)

    Endometrioma maximal diameter will be assessed by the same ultrasonographer (Dr. DB Nguyen) at each hospital visit, using a standardized technique, with 3-dimensional volumetric assessment.

    Time frame: pre-study, 3-months of treatment

  4. Incidence of amenorrhea

    Incidence of amenorrhea will be evaluated by having the participant complete a questionnaire at each hospital visit. * If they have gotten their period in the last 3 months: measured by (yes/no) * The frequency of spotting in the last month: measured by a 4-point likert scale (Never/Rarely/Occasionally/Often)

    Time frame: pre-study, 3-months of treatment, 6-months of treatment

  5. Change in patient reported endometriosis symptoms

    Change of endometriosis symptoms will be evaluated by monitoring the changes in participants's responses to the modified Biberoglu \& Behrman (B\&B) scale questionnaire. This is a validated scale that evaluates endometriosis pain by patient's self-assessment of three pain symptoms (dysmenorrhea, dyspareunia, and chronic pelvic pain) on a 4-point likert scale (none=0/mild=1/moderate=2/severe=3). Minimum value: 0 --\> best outcome Maximum value: 9 --\> worst outcome

    Time frame: pre-study, 3-months of treatment, 6-months of treatment

  6. Change in weight

    Weight will be measured by a research coordinator or nurse at each hospital visit.

    Time frame: pre-study, 3-months of treatment, 6-months of treatment

  7. Change in blood pressure

    Blood pressure will be measured by a research coordinator or nurse at each hospital visit.

    Time frame: pre-study, 3-months of treatment, 6-months of treatment

  8. Incidence of adverse effects (safety, tolerability)

    Incidence of adverse effects (yes/no) including: nausea/vomiting, edema, breast tenderness, headache, cramps/bloating, mood swings (specified), as well as any unexpected adverse effects will be evaluated by having the participant complete a questionnaire at each hospital visit after starting estetrol/drospirenone.

    Time frame: 3-months of treatment, 6-months of treatment

  9. Compliance

    Drug compliance will be evaluated by having the participant complete a questionnaire at each hospital visit after starting estetrol/drospirenone. * If they have been taking the prescribed dosage of 1 oral tablet of estetrol/drospirenone a day (yes/no) * If they have been taking the prescribed dosage at the same time every day (yes/no) * How often they miss a pill, on a 4-point likert scale (Never/Rarely/Occasionally/Often)

    Time frame: 3-months of treatment, 6-months of treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Liao C, Pal L. Novel Pharmacotherapies for Menopausal Symptoms. Obstet Gynecol. 2025 Oct 1;146(4):473-486. doi: 10.1097/AOG.0000000000006025. Epub 2025 Aug 7. PubMed 40773756 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Dec 2024 (actual). Primary completion is estimated for Jul 2027, 31 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 3, 2026: primary completion Nov 2026 → Jul 2027 and completion Dec 2026 → Aug 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2023
First posted
May 1, 2023
StartActual
Dec 3, 2024
Primary completionEst.
Jul 2027was Nov 2026
CompletionEst.
Aug 2027was Dec 2026
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Nov 2026→Jul 2027
Nov 3, 2026
Study completion
Dec 2026→Aug 2027
Nov 3, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 40773756 ↗
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 40773756 ↗
    Primary completion Nov 2026→Jul 2027
    Study completion Dec 2026→Aug 2027
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05837624
Lead sponsor
Andrew Zakhari
Responsible party
Andrew Zakhari (Dr. Andrew Zakhari, MD, FRCSC, MGSC, McGill University Health Centre/Research Institute of the McGill University Health Centre) — Sponsor-investigator
First posted
May 1, 2023
Start date
Dec 3, 2024
Primary completion
Jul 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Nov 3, 2026

Study contacts

Andrew Zakhari, M.D.
Contact
andrew.zakhari@mcgill.ca
5142288889
Cassandra Della Rocca, BSc.
Contact
cassandra.dellarocca@rimuhc.ca
Andrew Zakhari, M.D.
principal investigator · McGill University Health Centre/Research Institute of the McGill University Health Centre

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Estetrol · Drospirenone

Start the discussion